Effects of NMDA antagonism on striatal dopamine release in healthy subjects

Application of a novel PET approach

Alan Breier, Caleb M. Adler, Neil Weisenfeld, Tung Ping Su, Igor Elman, Lisa Picken, Anil K. Malhotra, David Pickar

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

Agents that antagonize the glutamatergic N-methyl-d-aspartate (NMDA) receptor, such as phenylcyclidine (PCP) and ketamine, produce a behavioral state in healthy volunteers that resembles some aspects of schizophrenia. A dysfunction in NMDA-dopaminergic interactions has been proposed as a mechanism for these behavioral effects. In this study, we examined the effects of ketamine on striatal dopamine release in healthy human subjects with a novel 11C-raclopride/PET displacement paradigm and compared these effects to administration of saline and the direct-acting dopamine agonist amphetamine. We found that the percent decreases (mean ± SD) in specific 11C-raclopride binding from baseline for ketamine (11.2 ± 8.9) was greater than for saline (1.9 ± 3.7) (t = 2.4, df = 13, P = 0.003) indicating that ketamine caused increases in striatal synaptic dopamine concentrations. Ketamine-related binding changes were not significantly different than the decreases in percent change (mean ± SD) in specific 11C-raclopride binding caused by amphetamine (15.5 ± 6.2) (t = 1.3, df = 19, P = 0.21). Ketamine- induced changes in 11C-raclopride-specific binding were significantly correlated with induction of schizophrenia-like symptoms. The implications of this brain imaging method for studies of schizophrenia and the mechanism of action of antipsychotic drugs are discussed.

Original languageEnglish (US)
Pages (from-to)142-147
Number of pages6
JournalSynapse
Volume29
Issue number2
DOIs
StatePublished - Jun 1998

Fingerprint

Corpus Striatum
Ketamine
Aspartic Acid
Raclopride
Dopamine
Healthy Volunteers
Schizophrenia
Amphetamine
Excitatory Amino Acid Agents
Dopamine Agonists
Neuroimaging
Antipsychotic Agents

Keywords

  • C-raclopride
  • Dopamine
  • Glutamate
  • NMDA
  • Positron emission tomography
  • Schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)
  • Physiology
  • Pharmacology

Cite this

Effects of NMDA antagonism on striatal dopamine release in healthy subjects : Application of a novel PET approach. / Breier, Alan; Adler, Caleb M.; Weisenfeld, Neil; Su, Tung Ping; Elman, Igor; Picken, Lisa; Malhotra, Anil K.; Pickar, David.

In: Synapse, Vol. 29, No. 2, 06.1998, p. 142-147.

Research output: Contribution to journalArticle

Breier, Alan ; Adler, Caleb M. ; Weisenfeld, Neil ; Su, Tung Ping ; Elman, Igor ; Picken, Lisa ; Malhotra, Anil K. ; Pickar, David. / Effects of NMDA antagonism on striatal dopamine release in healthy subjects : Application of a novel PET approach. In: Synapse. 1998 ; Vol. 29, No. 2. pp. 142-147.
@article{3f93ec07865143449b811746fb7746b4,
title = "Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach",
abstract = "Agents that antagonize the glutamatergic N-methyl-d-aspartate (NMDA) receptor, such as phenylcyclidine (PCP) and ketamine, produce a behavioral state in healthy volunteers that resembles some aspects of schizophrenia. A dysfunction in NMDA-dopaminergic interactions has been proposed as a mechanism for these behavioral effects. In this study, we examined the effects of ketamine on striatal dopamine release in healthy human subjects with a novel 11C-raclopride/PET displacement paradigm and compared these effects to administration of saline and the direct-acting dopamine agonist amphetamine. We found that the percent decreases (mean ± SD) in specific 11C-raclopride binding from baseline for ketamine (11.2 ± 8.9) was greater than for saline (1.9 ± 3.7) (t = 2.4, df = 13, P = 0.003) indicating that ketamine caused increases in striatal synaptic dopamine concentrations. Ketamine-related binding changes were not significantly different than the decreases in percent change (mean ± SD) in specific 11C-raclopride binding caused by amphetamine (15.5 ± 6.2) (t = 1.3, df = 19, P = 0.21). Ketamine- induced changes in 11C-raclopride-specific binding were significantly correlated with induction of schizophrenia-like symptoms. The implications of this brain imaging method for studies of schizophrenia and the mechanism of action of antipsychotic drugs are discussed.",
keywords = "C-raclopride, Dopamine, Glutamate, NMDA, Positron emission tomography, Schizophrenia",
author = "Alan Breier and Adler, {Caleb M.} and Neil Weisenfeld and Su, {Tung Ping} and Igor Elman and Lisa Picken and Malhotra, {Anil K.} and David Pickar",
year = "1998",
month = "6",
doi = "10.1002/(SICI)1098-2396(199806)29:2<142::AID-SYN5>3.0.CO;2-7",
language = "English (US)",
volume = "29",
pages = "142--147",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Effects of NMDA antagonism on striatal dopamine release in healthy subjects

T2 - Application of a novel PET approach

AU - Breier, Alan

AU - Adler, Caleb M.

AU - Weisenfeld, Neil

AU - Su, Tung Ping

AU - Elman, Igor

AU - Picken, Lisa

AU - Malhotra, Anil K.

AU - Pickar, David

PY - 1998/6

Y1 - 1998/6

N2 - Agents that antagonize the glutamatergic N-methyl-d-aspartate (NMDA) receptor, such as phenylcyclidine (PCP) and ketamine, produce a behavioral state in healthy volunteers that resembles some aspects of schizophrenia. A dysfunction in NMDA-dopaminergic interactions has been proposed as a mechanism for these behavioral effects. In this study, we examined the effects of ketamine on striatal dopamine release in healthy human subjects with a novel 11C-raclopride/PET displacement paradigm and compared these effects to administration of saline and the direct-acting dopamine agonist amphetamine. We found that the percent decreases (mean ± SD) in specific 11C-raclopride binding from baseline for ketamine (11.2 ± 8.9) was greater than for saline (1.9 ± 3.7) (t = 2.4, df = 13, P = 0.003) indicating that ketamine caused increases in striatal synaptic dopamine concentrations. Ketamine-related binding changes were not significantly different than the decreases in percent change (mean ± SD) in specific 11C-raclopride binding caused by amphetamine (15.5 ± 6.2) (t = 1.3, df = 19, P = 0.21). Ketamine- induced changes in 11C-raclopride-specific binding were significantly correlated with induction of schizophrenia-like symptoms. The implications of this brain imaging method for studies of schizophrenia and the mechanism of action of antipsychotic drugs are discussed.

AB - Agents that antagonize the glutamatergic N-methyl-d-aspartate (NMDA) receptor, such as phenylcyclidine (PCP) and ketamine, produce a behavioral state in healthy volunteers that resembles some aspects of schizophrenia. A dysfunction in NMDA-dopaminergic interactions has been proposed as a mechanism for these behavioral effects. In this study, we examined the effects of ketamine on striatal dopamine release in healthy human subjects with a novel 11C-raclopride/PET displacement paradigm and compared these effects to administration of saline and the direct-acting dopamine agonist amphetamine. We found that the percent decreases (mean ± SD) in specific 11C-raclopride binding from baseline for ketamine (11.2 ± 8.9) was greater than for saline (1.9 ± 3.7) (t = 2.4, df = 13, P = 0.003) indicating that ketamine caused increases in striatal synaptic dopamine concentrations. Ketamine-related binding changes were not significantly different than the decreases in percent change (mean ± SD) in specific 11C-raclopride binding caused by amphetamine (15.5 ± 6.2) (t = 1.3, df = 19, P = 0.21). Ketamine- induced changes in 11C-raclopride-specific binding were significantly correlated with induction of schizophrenia-like symptoms. The implications of this brain imaging method for studies of schizophrenia and the mechanism of action of antipsychotic drugs are discussed.

KW - C-raclopride

KW - Dopamine

KW - Glutamate

KW - NMDA

KW - Positron emission tomography

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0031947285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031947285&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2396(199806)29:2<142::AID-SYN5>3.0.CO;2-7

DO - 10.1002/(SICI)1098-2396(199806)29:2<142::AID-SYN5>3.0.CO;2-7

M3 - Article

VL - 29

SP - 142

EP - 147

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 2

ER -